SEQUX - Sequoia

Nasdaq - Nasdaq Delayed Price. Currency in USD
178.40
+0.17 (+0.10%)
At close: 8:00PM EDT
Stock chart is not supported by your current browser
Previous Close178.23
YTD Return1.30%
Expense Ratio (net)1.00%
CategoryLarge Growth
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingBelow Average
Sustainability RatingN/A
Net Assets4.18B
Beta (3y)0.43
Yield0.00%
5y Average ReturnN/A
Holdings Turnover18.00%
Last Dividend0.00
Average for CategoryN/A
Inception DateJul 15, 1970
  • Sequoia-Backed Design Startup Canva Has 'Ambitious Plans,' CEO Says
    Bloomberg Video4 months ago

    Sequoia-Backed Design Startup Canva Has 'Ambitious Plans,' CEO Says

    Jan.09 -- Melanie Perkins, Cava's co-founder and chief executive officer, discusses the startup's strategy with Bloomberg's Haidi Lun and Betty Liu on "Bloomberg Daybreak: Australia."

  • Morningstar2 months ago

    Sorting the Rebels From the Conformists

    Tracking error helps you set expectations.

  • PR Newswire7 months ago

    Milberg LLP Announces Investigation of Sequoia Fund

    NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Milberg LLP, an investor and consumer protection firm, is investigating whether the Sequoia Fund (SEQUX) damaged its shareholders in violation of law by breaching obligations to them with respect to the size of its investments in Valeant Pharmaceuticals International Inc. ("Valeant"). Pursuant to Sequoia Fund's concentration policy, which is stated in its offering prospectus, Sequoia Fund was not allowed to invest more than 25% of Sequoia's assets in one industry.  In 2010, however, Sequoia Fund invested in Valeant to the tune of 9.2% of the fund's assets. In 2015, Valeant was engulfed in a scandal stemming from its practice of acquiring drugs and raising prices dramatically, drawing significant political and public scorn.  Accusations soon followed by investigative journalists, investments analysts, and short sellers, of questionable accounting and business practices, which caused Valeant's stock price to plummet.